The evidence for glycine preventing muscle loss during GLP-1 therapy is limited, but the amino acid is safe at the doses included in these formulations
Its primary pharmacological characterization was published in European Journal of Endocrinology (PMID 9849822), where the authors identified it as the first growth-hormone-secretagogue receptor (GHSR-1a) agonist achieving GH-release selectivity comparable to GHRH in animal models
Compare BPC-157 by mechanism, evidence strength, expected timeline, side-effect profile, and whether its primary use case matches your goal
What is carnitine and what is it for
Follow the recommended treatment schedule provided by your healthcare professional to achieve optimal results
Results A total of 35,488 adult KTRs with T2DM (mean [SD] age, 57.7 [12.2] years